NEWS RELEASE: Halifax firm improves lives and provides faster results with new technology

Alentic Microscience Inc. commercializes its blood diagnostic device for medical settings March 4, 2019 – Halifax, NS – Atlantic Canada Opportunities Agency Cutting-edge ideas in life sciences are reaching the marketplace faster than ever, providing Canadians with less invasive and more effective treatment options that improve patient outcomes. Determined to provide mobile healthcare solutions that give immediate results, Alentic Microscience Inc. has developed a pocket-sized diagnostic device that can generate test results in under five minutes, from any location, using only a drop of blood from a pinprick. Conceived for medical diagnostics, Alentic’s technology was chosen by the Canadian Space Agency to conduct immunological research in real-time aboard the International Space Station. Alentic is now commercializing its technology to be used in hospitals, clinics, veterinary settings or in the field. The device uses patented technology to analyze a tiny quantity of blood, producing high quality blood test results immediately at patient point-of-care. The device can perform different types of tests rapidly, which will improve patient care, reduce wait times, lower costs and increase healthcare efficiencies. Today, Andy Fillmore, Parliamentary Secretary to the Minister of Canadian Heritage and Multiculturalism and Member of Parliament for Halifax, on behalf of the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for the Atlantic Canada Opportunities Agency (ACOA), announced $2,992,162 in Government of Canada support to Alentic Microscience Inc. for the project. This investment builds on commitments made by the Government of Canada and the four Atlantic Provinces to drive economic growth in the region through the Atlantic Growth Strategy, which supports strategic investments that build on the region’s competitive advantages, including its growing innovation ecosystem and skilled workforce. Quotes: “In a time of rapid technological change and global interconnectedness, we have an opportunity to leverage our healthcare innovations to achieve even greater impact through advances in life sciences. With commitment and bold action, Atlantic Canada can be a frontrunner for the country, and the world, in providing quality bio-innovations that attract investment and talent, advance our economic prosperity and provide better healthcare to Canadians.” – The Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for ACOA “Alentic’s technology is working to transform traditional patient care with shorter wait times for test results. This innovative tool has the potential to improve the lives of thousands of Canadians, particularly those who have health conditions such as heart disease, anemia and immune disorders, for which frequent blood tests are vital to properly manage these illnesses.” – Andy Fillmore, Parliamentary Secretary to the Minister of Canadian Heritage and Multiculturalism and Member of Parliament for Halifax “All of us at Alentic Microscience are deeply grateful to ACOA for their enabling financial support. This contribution will allow us to achieve critical research, development and commercialization milestones on our path to selling Alentic’s revolutionary diagnostic devices in Canada and abroad. The money further allows us to grow our superb team as we approach market entry.” – Alan Fine, CEO, Alentic Microscience Inc. Quick Facts: • Alentic Microscience is receiving a $2,992,162 repayable contribution through ACOA’s Business Development Program (BDP). • The funding will help create six jobs, including a biological engineer, a software developer and an embedded systems engineer, in addition to maintaining 15 jobs, to help with the planning, detailed design, prototype assembly, testing and clinical trials of new devices. • Alentic’s technology is fully operational for specific cellular analyses currently used in medical and veterinary settings. • In collaboration with Honeywell International Inc., Alentic successfully obtained a multi-million dollar contract with the Canadian Space Agency to develop specific diagnostic tests and a device to monitor astronauts’ immune systems in real time, an important task that was previously impossible. • Alentic Microscience Inc. has been granted ten patents in the United States, one in Canada and one in China, with many more patents in progress. • The BDP primarily assists Atlantic Canadian entrepreneurs who want to start a business, increase productivity or improve operations. • The Business Development Program continues to build on the objectives of the Innovation and Skills Plan, a multi-year strategy to create well-paying jobs for the middle class and those working hard to join it. Associated Links:Bio-Analyzer: Instant biomedical results from space to Earth Contacts: Chris Brooks Director, Communications and Outreach Atlantic Canada Opportunities Agency 902-426-9417 / 902-830-3839 (cell) chris.brooks@canada.ca Alan Fine CEO Alentic Microscience Inc. 902-407-0827 / 902-440-3825 afine@alentic.com]]>

NEWS RELEASE: BioVectra Inc. announces a $144.6 million expansion project, including a $37.5 million contribution through the Government of Canada’s Strategic Innovation Fund

BioVectra Inc. announces a $144.6 million expansion project, including a $37.5 million contribution through the Government of Canada’s Strategic Innovation Fund — Prime Minister Justin Trudeau visits BioVectra to announce Government of Canada investment in Atlantic Canadian CDMO and high-skilled jobs creation in the region — Charlottetown, Prince Edward Island, Canada (March 4, 2019) – Today, BioVectra Inc., an Atlantic Canadian Contract Development and Manufacturing Organization (CDMO), announced a five-year, $144.6 million (CAD) expansion project to enhance its Biopharmaceutical capabilities in both Charlottetown, Prince Edward Island and Windsor, Nova Scotia. Prime Minister, Justin Trudeau, visited BioVectra in Charlottetown to announce a $37.5 million contribution from the Government of Canada through the Strategic Innovation Fund (SIF). The $37.5 million contribution represents the single largest SIF Project ever awarded in Atlantic Canada. “Thanks to innovations in life sciences, Canadians are living longer, healthier lives than ever before. Canadian companies like BioVectra are creating new jobs and establishing themselves as global leaders in producing lifesaving treatments for serious illnesses that affect millions of people around the world. Today, we are not only investing in an innovative Canadian business, but also in Canadians and the future prosperity of our country.” – The Rt. Hon. Justin Trudeau, Prime Minister of Canada More specifically, the project is intended to support BioVectra’s on-going Active Pharmaceutical Ingredients (APIs) production capacity expansion in Charlottetown, as well as an expansion of its Biologics capabilities in Windsor, including a mammalian cell culture facility. Over the project’s five-year lifespan, 150 high-skilled, full-time jobs are expected to be created on Prince Edward Island and in Nova Scotia. “We are pleased to announce plans to create 150 additional jobs, 110 to be located at our Windsor site and 40 in Charlottetown,” said BioVectra President, Oliver Technow. “This is an extremely proud day for BioVectra, and we are deeply appreciative of the government’s support. Since 2015, we have invested approximately $25 million per year in expansions and technologies that have vastly enhanced our capabilities. Today’s announcement is a continuation of our commitment to growth right here in Atlantic Canada!” As a trusted and innovative partner, BioVectra’s global client base includes most of the top 20 biopharmaceutical companies in the world. “Our clients develop important, life-saving medicines for people all around the globe,” said BioVectra’s Windsor General Manager, Heather Delage. “This exciting expansion project is designed to help propel us toward being a top-tier player in the biologics field, where many therapies are advancing rapidly, and changing the way healthcare is delivered.” Beyond these expansion plans, BioVectra intends to complement its existing academic partnerships by forming additional collaborations with Canadian academic institutions. This investment includes reinforcing its future talent base by providing over 25 students with on-the-job training and internship opportunities on an annual basis. About BioVectra BioVectra is a CDMO that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, BioVectra has over 45 years of experience specializing in:

  • cGMP Microbial Fermentation
  • Complex Chemistry – High Potency APIs
  • Biologics
  • Formulation Development
For more information about BioVectra, please visit www.biovectra.com. Media Contact Jordan MacGregor Communications and Marketing Manager BioVectra Inc. Phone: 902-566-9116 ext. 6376 E-Mail: jmacgregor@biovectra.com Statements in this document that are not strictly historical, including statements regarding future business prospects, use of capital or the impact of any such events or developments, and any other statements regarding events or developments the company believes or anticipates will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. The forward-looking statements made herein speak only as of the date hereof and the company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.]]>

Entrevestor: Densitas Partners with U.S. Beta User

Halifax-based breast imaging analytics company Densitas has announced a collaboration with TeleMammography Specialists of Decatur, Georgia, that will improve the quality of breast screening offered to more than 60,000 women annually.
TeleMammography Specialists is an international teleradiology services provider and will be the first U.S. beta user for the new densitasquality solution, the company said in a statement. The product will improve the communications and information sharing needed to meet FDA guidelines.
TeleMammography Specialists also plan to implement the recently released densitasdensity automated breast density assessment software.
“Our goal is to provide tools that reduce the documentation, process and communication burdens of meeting EQUIP (FDA) guidelines and enables sustainable delivery of quality assurance across the mammography enterprise,” Mohamed Abdolell, CEO of Densitas, said in the statement.

See full article here

News Release: Precision BioLogic Launches Product to Improve Inhibitor Testing for People with Hemophilia A

HALIFAX, February 11, 2019—Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the availability of its new CRYOcheck Factor VIII Inhibitor Kit in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities last month.
The presence of factor VIII (FVIII) inhibitors reduces therapy effectiveness and is one of the most complex and costly complications for people with hemophilia A. Because of this, it is important for clinical laboratories to have a testing system that can accurately and precisely quantify FVIII inhibitors in patient samples.
Follow link above to read full release

See full news release here

Entrevestor: Beyond Food Raises $1M Round

See the full Entrevestor article here Halifax-based Beyond Food Inc. has closed a $1 million funding round to help it launch its system that will convert aging supermarket produce into a powdered food supplement. The company issued a press release this week saying it raised the money from a range of investors, including several National Hockey League players. The company’s website shows that it plans now to develop its first Zero Waste Pod this month and to launch its first partnership with a national supermarket chain in April. The company was formed two years ago with a core of sports and health enthusiasts. Its mission is to reduce food wastage, which now amounts to $31 billion a year in Canada alone, by finding supermarket produce that is about to be tossed out and using it to make a nutritional food supplement. It sells nutrition products under the brand TDF Sports. “We are building a revolutionary technology and company,” said Co-Founder and CEO Darren Burke in a statement. “Our Zero Waste Pod is a first in this race to tackle the large challenges related to the excessive food waste occurring in North America and beyond.”  ]]>

BioMedica Diagnostics Inc. Cornering the global market for blood testing kits

See original article on the Canadian Trade Commissioner Service Website BioMedica Diagnostics Inc. is well established as an exporter, with almost 100 percent of the sales of its blood coagulation testing kits, reagents and other products in more than 70 countries around the world.

(Photo: BioMedica Diagnostics Inc.)
But today the Windsor, Nova Scotia, company is stepping up its efforts abroad, with an aggressive growth plan that includes refocusing on existing markets and products, while extending its global reach and developing new disruptive technologies for the future. The firm has been given fast‑track status under a pilot program of the Canadian Trade Commissioner Service (TCS) that will provide resources to help it produce more revenues and generate additional jobs in the community. “We’d like to expand our international presence two- to three‑fold over the next few years,” says Lauren Iannetti, BioMedica’s vice‑president of business development, noting that the private company’s strategy is based on selecting distribution partners in the field, with the assistance of the TCS, that can help it grow. “We want to be market leaders.” BioMedica was started in 1999 as a medical device company focused on bringing affordable health care to countries around the world in the field of haemostasis (bleeding) and thrombosis (clotting) in the body. Its plasma‑based products are sold through a network of distributors to laboratories and used in panels of tests. They are either directly marketed under the BioMedica brand or purchased by instrumentation companies, which then sell the products under their own labels. The company was revamped five years ago under a new president and CEO, Brian Jeffers, and it renewed its commitment to routine coagulation testing in the international market. Three years ago, BioMedica expanded to include a specialty coagulation testing line through a firm that it acquired in Stamford, Connecticut, which increased its offering to some 100 products.

Tips for life sciences companies looking to go global

Exporters looking to aggressively extend their global reach in a field such as medical devices need passion, drive and a good business plan that ensures they don’t over extend, the experts say. “The realistic thing is how much business can a company handle,” says Butch Postma, a trade commissioner who covers the life sciences sector in Atlantic Canada and is based in Charlottetown. “It’s a work in progress with all clients.” Companies looking at international markets have various support partners at home to assist with export readiness, Postma says. “As clients carry out their due diligence on potential markets, an excellent first step for them is to leverage the domestic TCS network in Canada.” The company’s information is verified in a client management system, he says, making the client aware of the TCS’s service offerings and carrying out an introduction to TCS officers abroad. “This is all part of the beginning steps as we support the client with a recommended strategy, contacts and focused intelligence for the market or markets identified.” The biggest challenge for small and medium enterprises (SMEs) is to get themselves known to new customers, he says, noting that many also “fall down on not following up” once they’ve made initial contacts. “Sometimes you have the president of the company who’s also the marketing guy, who’s also the finance guy. And when he gets back to the office the international business component takes a backseat, because there’s other things that demand his attention.” Aurora Polo, a trade commissioner in Barcelona whose responsibilities include Spain’s life sciences and health industries sector, says the best market-entry strategy for Canadian medical devices or diagnostics SMEs is “to identify a good distributor or commercial partner with the right knowledge of the market and industry sector.” It’s important for a potential partner to have contacts in both the public and private health-care sectors, with expertise in the regulatory framework for such devices. It’s also critical to have appropriate knowledge of the bid procurement structure and processes at the local, regional, national and international level. Having the right contacts and being able to provide adequate technical support are key, she says. “Visiting the market is also a must, as personal relations are important to establish long-standing solid business relations with distributors and commercial partners.”
Today the company has about 50 employees and it is transferring that U.S. operation to its location in Windsor, west of Halifax, where it occupies a former high school in an agricultural setting. “It allows us to lean into that aggressive growth space,” says Iannetti, noting that more than 98 percent of BioMedica’s products are exported, with the help of the TCS. “It’s an excellent resource,” she says of the TCS, which has chosen BioMedica for the six-month fast‑track pilot. The program is intended to give 20 firms priority service and help them grow. BioMedica has selected 15 countries to focus on, including 10 markets where the company is not very well established or “we think we can do more,” Iannetti says, among them Dubai, Spain and South Africa. There are also five brand‑new countries for BioMedica, including Mexico, India and Hungary. Iannetti says that in Spain, BioMedica has “dabbled here and there,” but it is now looking to advance significantly with the assistance of Aurora Polo, a trade commissioner in Barcelona who covers the country’s life sciences and health industries sector. The company faces hurdles there from language barriers to complex regulations for medical devices, Iannetti says. “We rely on Aurora to bring forward potential leads of companies that would be ideal partners for us.” Polo says Spain is among the top five countries in Europe in sales of medical devices, “however it is competitive, with many players who are all attracted by the market potential,” she says. “With our help, BioMedica has been able to establish contact with some of the top diagnostics medical device and health technologies distributors, commercial partners and manufacturers.” The majority of these have confirmed an interest in collaborating with BioMedica. Iannetti says the company replies on Polo’s guidance. “We’re the experts on our products, and we greatly rely on the trade commissioners to be experts on the in‑market details.” TCS specialists can check out leads and make introductions to possible distributors “rather than us making cold calls,” she says, which helps to “legitimize” the company. “If the trade commissioner can vet the potential partner and give it the thumbs up, that instantly eliminates many of our concerns.” The TCS organizes events, for example at Medica, a giant international trade show for the medical sector held each year in Düsseldorf, Germany. At the one in November 2018, BioMedica had 50‑plus side meetings, Iannetti says, many of which the TCS set up. It also offers assistance at home, through its regional office in Halifax. Butch Postma, a trade commissioner who covers the life sciences sector in Atlantic Canada and is based in Charlottetown, “has been a great champion of ours,” Iannetti says, from suggesting strategies to proposing new markets. “He’s on it.” Postma says the company is “an excellent user of the TCS,” and has been “making aggressive plays internationally,” from expanding its export targets to enhancing its market share in countries where it already has business. “They have a good business plan and from an international point of view they have a combination of product and people to really carry it out,’” says Postma, who calls himself “a matchmaker between the client and my colleagues abroad.” BioMedica’s Brian Jeffers says that the TCS has helped the company implement its global objectives. “The TCS, both here and in international markets, has been highly effective for us and a pleasure to work with,” says Jeffers. He is a member of the TCS industry Life Sciences Sector Advisory Group, which looks at trends and changes in the sector and offers guidance to help the TCS develop and deliver programs and services to life science exporters. BioMedica markets itself as “proudly Canadian,” Iannetti says. “There’s a view that Canada and our products are very high quality.” She hopes the TCS can help the company “navigate some of the trickier markets” and help with matters such as payment issues and logistics as the company increases its reach. It has a busy and active research & development team that’s looking at disruptive technologies, for instance new ways of doing blood coagulation testing, Iannetti says. BioMedica looks for well‑established distributors that are the “right fit,” says Iannetti, screening and selecting those that can act autonomously on its behalf. “We don’t want to have to hand hold and we don’t need to babysit them.” This makes it imperative that “the trade commissioners are on task so we’re confident we’re signing up the right partners,” she adds.
Subscribe to: E-magazine and RSS Feed Twitter@TCS_SDC Use #CanadExport
]]>